Austria - English - HMA (Heads of Medicines Agencies)

intervet deutschland gmbh - bacteroides nodosus serotypes a to i 10 µg - emulsion for injection - sheep food - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia vaccines)

Germany - English - HMA (Heads of Medicines Agencies)

intervet deutschland gmbh - bacteroides nodosus serotypes a to i 10 µg - emulsion for injection - sheep food - inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia vaccines)

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; macrogol 400; magnesium stearate; maize starch; povidone; calcium hydrogen phosphate - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole benzoate, quantity: 64 mg/ml - oral liquid, suspension - excipient ingredients: ethanol; monobasic sodium phosphate; aluminium magnesium silicate; methyl hydroxybenzoate; sucrose; propyl hydroxybenzoate; orange oil terpeneless; flavour - anaerobic infections treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. notes. 1. because of the slow absorption and delayed peak plasma level, flagyl suspension is not recommended for use in the acute situation. 2. metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis( intestinal and extraintestin

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: quinoline yellow aluminium lake; lactose monohydrate; magnesium stearate; disodium edetate; sodium starch glycollate; guar gum; colloidal anhydrous silica; ethylcellulose - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sodium starch glycollate; ethylcellulose; colloidal anhydrous silica; guar gum; magnesium stearate; disodium edetate - metronidazole is indicated in the oral treatment of: 1. urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently. 2. bacterial vaginosis. 3. all forms of amoebiasis (intestinal and extra-intestinal disease). 4. giardiasis. 5. acute ulcerative gingivitis. 6. anaerobic infections including: septicaemia, bacteraemia, brain abscess, necrotising pneumonia, osteomyelitis, puerperal sepsis, pelvic abscess, pelvic cellulitis and postoperative wound infections, in which the pathogens have been identified as bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronidazole may be used prophylactically to prevent infection by anaerobic organisms of the surgical site following appendicectomy, colonic surgery, vaginal hysterectomy, abdominal surgery in the presence of anaerobes in the peritoneal cavity and s

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

norbrook laboratories australia pty limited - amoxycillin as amoxycillin trihydrate; clavulanic acid as potassium clavulanate - parenteral liquid/solution/suspension - amoxycillin as amoxycillin trihydrate antibiotic active 140.0 mg/ml; clavulanic acid as potassium clavulanate antibiotic active 35.0 mg/ml - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - actinobacillus lignieresii | actinomyces bovis | bacillus anthracis | bacteroides spp. | bordetella bronchiseptica | campylobacter spp. | clostridium spp. | corynebacteria | escherichia coli (e. coli) | fusobacterium necrophorum | haemophilus spp. | klebsiella spp. | moraxella spp. | pasteurella spp. | peptostreptococcus spp. | proteus spp. | salmonella | staphylococci | streptococci | anaerobic bacteria | anthrax | canine cough syndrome | clostridium botulinum | clostridium chauvoei | clostridium fallax | clostridium feseri | clostridium hemolyticum | clostridium novyi | clostridium perfringens types | clostridium septicum | clostridium sordelli | clostridium sporogenes | clostridium tetani | haemophilus agni | haemophilus bovis | haemophilus parainfluenzae | haemophilus parasuis | haemophilus pleuropneumoniae | haemophilus somnus | haemophilus suis | including b-lactamase producin | infectious tracheobronchitis | pasterellosis | pasteurellosis | salmonellosis

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - clindamycin as clindamycin hydrochloride - oral solution/suspension - clindamycin as clindamycin hydrochloride antibiotic active 25.0 mg/ml - antibiotic & related - cat | dog | bitch | castrate | cat - queen | cat - tom | kitten | puppy - abscess | actinomyces spp. | bacteroides spp. | clostridium spp. | dental infection | fusobacterium spp. | osteomyelitis | peptostreptococcus spp. | propionibacterium spp. | staphylococcus aureus | staphylococcus spp. | streptococcus spp. | wound infections | abscesses | anaerobic bacteria | clostridium botulinum | clostridium chauvoei | clostridium fallax | clostridium feseri | clostridium hemolyticum | clostridium novyi | clostridium perfringens types | clostridium septicum | clostridium sordelli | clostridium sporogenes | clostridium tetani | including b-lactamase producin | staphylococcosis

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tigecycline - powder for solution for infusion - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, clostridium perfringens, and peptostreptococcus micros.community-acquired bacterial pneumonia:community-acquired bacterial pneumonia caused by streptococcus pneumoniae (penicillin susceptible isolates), including cases with concurrent bacteremia, haemophilus influenzae (beta-lactamase negative isolates), and legionella pneumophila.

Israel - English - Ministry of Health

zoetis israel holding b.v., israel - cefovicin as sodium salt - powder and solvent for solution for injection - cefovicin as sodium salt 80 mg/dose - dogs : for the treatment of skin and soft tissue infections including pyoderma wounds and abscesses associated with staphylococcus intermedius beta-haemolytic streptococci escherichia coli and/or pasteurella multocida. for the treatment of urinary tract infections associated with escherichia coli and/or proteus spp.as adjunctive treatment to mechanical or surgical periodontal therapy of severe infections of the gingival and periodontal tissues associated with porphyromonas spp. and prevotella spp. cats : for the treatment of skin and soft tissue abscesses and wounds associated with pasteurella multocida fusobacterium spp. bacteroides spp. prevotella oralis beta-haemolytic streptococci and/or staphylococcus intermedius. for the treatment of urinary tract infections associated with escherichia coli.